Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ISCHSTR
MCID: STR067
MIFTS: 81

Stroke, Ischemic (ISCHSTR)

Categories: Cardiovascular diseases, Genetic diseases, Neuronal diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Stroke, Ischemic

About this section

MalaCards integrated aliases for Stroke, Ischemic:

Name: Stroke, Ischemic 57 39 36
Cerebral Infarction 57 39 11 73 53 43 14 71 31
Stroke 57 52 53 5 41 2 63 16 75
Ischemic Stroke 57 73 28 5 41 71
Cerebrovascular Accident 57 39 73 71
Cerebral Infarction, Susceptibility to 57 12 5
Stroke, Ischemic, Susceptibility to 57 38
Cerebral Infarct 11 14
Ischemic Stroke, Susceptibility to 57
Ischemic Cerebrovascular Accident 71
Stroke, Susceptibility to 57
Cva - Cerebral Infarction 11
Ischstr 73

Characteristics:


Inheritance:

Multifactorial predisposition 57

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Cardiovascular diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:3526
OMIM® 57 601367
MeSH 43 D002544
NCIt 49 C50486
SNOMED-CT 68 195188006
SNOMED-CT via HPO 69 230690007
UMLS 71 C0007785 C0038454 C0948008 more
Sources

Summaries for Stroke, Ischemic

About this section

MedlinePlus: 41 What is a stroke? A stroke happens when there is a loss of blood flow to part of the brain. Your brain cells cannot get the oxygen and nutrients they need from blood, and they start to die within a few minutes. This can cause lasting brain damage, long-term disability, or even death. If you think that you or someone else is having a stroke, call 911 right away. Immediate treatment may save someone's life and increase the chances for successful rehabilitation and recovery. What are the types of stroke? There are two types of stroke: Ischemic stroke is caused by a blood clot that blocks or plugs a blood vessel in the brain. This is the most common type; about 80% of strokes are ischemic. Hemorrhagic stroke is caused by a blood vessel that breaks and bleeds into the brain Another condition that's similar to a stroke is a transient ischemic attack (TIA). It's sometimes called a "mini-stroke." TIAs happen when the blood supply to the brain is blocked for a short time. The damage to the brain cells isn't permanent, but if you have had a TIA, you are at a much higher risk of having a stroke. Who is at risk for a stroke? Certain factors can raise your risk of a stroke. The major risk factors include: High blood pressure. This is the primary risk factor for a stroke. Diabetes. Heart diseases. Atrial fibrillation and other heart diseases can cause blood clots that lead to stroke. Smoking. When you smoke, you damage your blood vessels and raise your blood pressure. A personal or family history of stroke or TIA. Age. Your risk of stroke increases as you get older. Race and ethnicity. African Americans have a higher risk of stroke. There are also other factors that are linked to a higher risk of stroke, such as: Alcohol and illegal drug use Not getting enough physical activity High cholesterol Unhealthy diet Having obesity What are the symptoms of stroke? The symptoms of stroke often happen quickly. They include: Sudden numbness or weakness of the face, arm, or leg (especially on one side of the body) Sudden confusion, trouble speaking, or understanding speech Sudden trouble seeing in one or both eyes Sudden difficulty walking, dizziness, loss of balance or coordination Sudden severe headache with no known cause If you think that you or someone else is having a stroke, call 911 right away. How are strokes diagnosed? To make a diagnosis, your health care provider will: Ask about your symptoms and medical history Do a physical exam, including a check of Your mental alertness Your coordination and balance Any numbness or weakness in your face, arms, and legs Any trouble speaking and seeing clearly Run some tests, which may include Diagnostic imaging of the brain, such as a CT scan or MRI Heart tests, which can help detect heart problems or blood clots that may have led to a stroke. Possible tests include an electrocardiogram (EKG) and an echocardiography. What are the treatments for stroke? Treatments for stroke include medicines, surgery, and rehabilitation. Which treatments you get depend on the type of stroke and the stage of treatment. The different stages are: Acute treatment, to try to stop a stroke while it is happening Post-stroke rehabilitation, to overcome the disabilities caused by the stroke Prevention, to prevent a first stroke or, if you have already had one, prevent another stroke Acute treatments for ischemic stroke are usually medicines: You may get tPA, (tissue plasminogen activator), a medicine to dissolve the blood clot. You can only get this medicine within 4 hours of when your symptoms started. The sooner you can get it, the better your chance of recovery. If you cannot get that medicine, you may get medicine that helps stop platelets from clumping together to form blood clots. Or you may get a blood thinner to keep existing clots from getting bigger. If you have carotid artery disease, you may also need a procedure to open your blocked carotid artery Acute treatments for hemorrhagic stroke focus on stopping the bleeding. The first step is to find the cause of bleeding in the brain. The next step is to control it: If high blood pressure is the cause of bleeding, you may be given blood pressure medicines. If an aneurysm if the cause, you may need aneurysm clipping or coil embolization. These are surgeries to prevent further leaking of blood from the aneurysm. It also can help prevent the aneurysm from bursting again. If an arteriovenous malformation (AVM) is the cause of a stroke, you may need an AVM repair. An AVM is a tangle of faulty arteries and veins that can rupture within the brain. An AVM repair may be done through Surgery Injecting a substance into the blood vessels of the AVM to block blood flow Radiation to shrink the blood vessels of the AVM Stroke rehabilitation can help you relearn skills you lost because of the damage. The goal is to help you become as independent as possible and to have the best possible quality of life. Prevention of another stroke is also important, since having a stroke increases the risk of getting another one. Prevention may include heart-healthy lifestyle changes and medicines. Can strokes be prevented? If you have already had a stroke or are at risk of having a stroke, you can make some heart-healthy lifestyle changes to try to prevent a future stroke: Eating a heart-healthy diet Aiming for a healthy weight Managing stress Getting regular physical activity Quitting smoking Managing your blood pressure and cholesterol levels If these changes aren't enough, you may need medicine to control your risk factors. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Stroke, Ischemic, also known as cerebral infarction, is related to sneddon syndrome and brain small vessel disease 1, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Stroke, Ischemic is F5 (Coagulation Factor V), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Defects of contact activation system (CAS) and kallikrein/kinin system (KKS). The drugs Progesterone and Spironolactone have been mentioned in the context of this disorder. Affiliated tissues include Bone and Brain, and related phenotypes are stroke and Increased free cholesterol

PubMed Health : 63 Stroke: A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked. Without oxygen, brain cells start to die after a few minutes. Sudden bleeding in the brain also can cause a stroke if it damages brain cells. If brain cells die or are damaged because of a stroke, symptoms occur in the parts of the body that these brain cells control. Examples of stroke symptoms include sudden weakness; paralysis or numbness of the face, arms, or legs (paralysis is an inability to move); trouble speaking or understanding speech; and trouble seeing. A stroke is a serious medical condition that requires emergency care. A stroke can cause lasting brain damage, long-term disability, or even death. If you think you or someone else is having a stroke, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts.

OMIM®: 57 A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. It is said to be the third leading cause of death in the United States. Gunel and Lifton (1996) noted that about 20% of strokes are hemorrhagic, resulting in bleeding into the brain. Ischemic strokes, resulting from vascular occlusion, account for the majority of strokes. Bersano et al. (2008) reviewed genetic polymorphisms that have been implicated in the development of stroke. Candidate genes include those involved in hemostasis (see, e.g., F5; 612309), the renin-angiotensin-aldosterone system (see, e.g., ACE; 106180), homocysteine (see, e.g., MTHFR; 607093), and lipoprotein metabolism (see, e.g., APOE; 107741). See also hemorrhagic stroke, or intracerebral hemorrhage (ICH; 614519). (601367) (Updated 08-Dec-2022)

NINDS: 52 A stroke occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when they no longer receive oxygen and nutrients from the blood or there is sudden bleeding into or around the brain. The symptoms of a stroke include sudden numbness or weakness, especially on one side of the body; sudden confusion or trouble speaking or understanding speech; sudden trouble seeing in one or both eyes; sudden trouble with walking, dizziness, or loss of balance or coordination; or sudden severe headache with no known cause. There are two forms of stroke: ischemic - blockage of a blood vessel supplying the brain, and hemorrhagic - bleeding into or around the brain.

CDC: 2 A stroke, sometimes called a brain attack, occurs when something blocks blood supply to part of the brain or when a blood vessel in the brain bursts. In either case, parts of the brain become damaged or die. A stroke can cause lasting brain damage, long-term disability, or even death. Learn more about what causes stroke and what happens during a stroke.

UniProtKB/Swiss-Prot: 73 A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.

Disease Ontology: 11 A cerebrovascular disease that is characterized by an area of necrotic tissue in the brain resulting from a blockage or narrowing in the arteries supplying blood and oxygen to the brain.

Wikipedia: 75 A stroke is a medical condition in which poor blood flow to the brain causes cell death. There are two... more...
Sources

Related Diseases for Stroke, Ischemic

About this section

Diseases related to Stroke, Ischemic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2756)
# Related Disease Score Top Affiliating Genes
1 sneddon syndrome 33.3 NOTCH3 F5 F2 ADA2
2 brain small vessel disease 1 32.4 NOTCH3 MT-TL1
3 intracranial berry aneurysm 31.8 PLAT NOS3 F2
4 moyamoya disease 1 31.8 PLAT NOTCH3 F2
5 patent foramen ovale 31.6 PLAT NOTCH3 FBN1 F5 F2 ACE
6 transient cerebral ischemia 31.6 PLAT NOTCH3 F2 ACE
7 vascular disease 31.6 PLAT NOTCH3 NOS3 LDLR FGB FBN1
8 cerebral sinovenous thrombosis 31.5 F5 F2
9 acute myocardial infarction 31.4 PLAT NOS3 F2 CDKN2B-AS1 APOB ACE
10 peripheral vascular disease 31.4 PLAT NOS3 F2 APOB ACE
11 pulmonary embolism 31.4 PLAT FGB F5 F2 ACE
12 basilar artery occlusion 31.3 PLAT ACE
13 lipid metabolism disorder 31.3 NOS3 LDLR CD36 APOB ACE
14 migraine with aura 31.3 NOTCH3 NOS3 F5 F2 ACE
15 nervous system disease 31.3 PLAT PIK3CA NOTCH3 NOS3 MIAT F2
16 hypercholesterolemia, familial, 1 31.2 NOS3 LDLR APOB ACE
17 peripheral artery disease 31.2 NOS3 CDKN2B-AS1 APOB ACE
18 nonbacterial thrombotic endocarditis 31.2 PLAT F2
19 sleep apnea 31.2 NOS3 APOB ACE
20 cerebral palsy 31.2 PLAT NOS3 MT-TL1 FGB F5 F2
21 lipoprotein quantitative trait locus 31.2 PLAT NOS3 LDLR FBN1 F2 CDKN2B-AS1
22 migraine with or without aura 1 31.2 NOTCH3 NOS3 MT-TL1 F2 ACE
23 aortic aneurysm 31.2 NOS3 FBN1 F2 CDKN2B-AS1 ACE
24 hemopericardium 31.2 PLAT FBN1 F2
25 retinal artery occlusion 31.2 F5 F2 ACE
26 substance abuse 31.1 MIAT F2 ACE
27 cerebrovascular disease 31.1 PLAT NOTCH3 F5 F2 APOB ADA2
28 coronary heart disease 1 31.1 LDLR APOB ACE
29 thrombophilia 31.1 PLAT NOS3 FGB F5 F2 ACE
30 central retinal artery occlusion 31.1 PLAT F2 ADA2
31 pre-eclampsia 31.1 PLAT NOS3 MALAT1 F5 F2 ACE
32 carotid stenosis 31.1 NOS3 CDKN2B-AS1 ACE
33 disseminated intravascular coagulation 31.1 PLAT F5 F2
34 mitral valve disease 31.0 FBN1 F2 ACE
35 varicose veins 31.0 PLAT FBN1 F5 F2
36 type 2 diabetes mellitus 31.0 PLAT PIK3CA NOS3 LDLR FGB F5
37 thrombosis 31.0 PLAT NOS3 FGB F5 F2
38 antiphospholipid syndrome 31.0 PLAT F5 F2
39 nonobstructive coronary artery disease 31.0 NOS3 CDKN2B-AS1 APOB ACE
40 familial hypercholesterolemia 31.0 NOS3 LDLR FGB APOB
41 orthostatic intolerance 31.0 NOS3 FBN1 ACE
42 atrial heart septal defect 31.0 PLAT FBN1 F2 ACE
43 mitral valve insufficiency 31.0 FBN1 F2 ACE
44 eclampsia 31.0 NOS3 F2 ACE
45 intracranial embolism 31.0 PLAT F2 ACE
46 carotid artery disease 31.0 PLAT APOB ACE
47 mitral valve stenosis 31.0 PLAT F2 ACE
48 aspiration pneumonia 31.0 PLAT F2 ACE
49 familial hyperlipidemia 31.0 LDLR APOB ACE
50 angina pectoris 31.0 PLAT NOS3 ACE

Graphical network of the top 20 diseases related to Stroke, Ischemic:



Diseases related to Stroke, Ischemic
Sources

Symptoms & Phenotypes for Stroke, Ischemic

About this section

Human phenotypes related to Stroke, Ischemic:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 stroke 30 HP:0001297

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neuro:
stroke
motor, sensory and/or cognitive function loss

Clinical features from OMIM®:

601367 (Updated 08-Dec-2022)

UMLS symptoms related to Stroke, Ischemic:


tremor; back pain; angina pectoris; chest pain; headache; syncope; edema; pain; chronic pain; sciatica; seizures; vertigo/dizziness; equilibration disorder; sleeplessness

GenomeRNAi Phenotypes related to Stroke, Ischemic according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased free cholesterol GR00340-A-2 8.62 APOB F5

MGI Mouse Phenotypes related to Stroke, Ischemic:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.39 ACE ACSL4 ALOX5AP APOB CD36 F2
2 nervous system MP:0003631 10.29 APOB CD36 F2 F5 FBN1 LDLR
3 growth/size/body region MP:0005378 10.28 ACE ACSL4 APOB CD36 F2 F5
4 cardiovascular system MP:0005385 10.18 ACE ACSL4 APOB CD36 F2 F5
5 muscle MP:0005369 10.15 APOB CD36 F2 FBN1 LDLR NOS3
6 endocrine/exocrine gland MP:0005379 10.14 ACE ACSL4 CD36 F2 FBN1 LDLR
7 behavior/neurological MP:0005386 10.1 ACE CD36 F2 F5 FBN1 LDLR
8 immune system MP:0005387 10.07 ACE ALOX5AP APOB CD36 F2 FBN1
9 adipose tissue MP:0005375 10.02 ACE CD36 F2 FBN1 LDLR NOS3
10 hematopoietic system MP:0005397 9.93 ACE ACSL4 ALOX5AP CD36 F2 FBN1
11 mortality/aging MP:0010768 9.8 ACE ACSL4 APOB CD36 F2 F5
12 integument MP:0010771 9.28 CD36 F2 F5 FBN1 LDLR NOTCH3
Sources

Drugs & Therapeutics for Stroke, Ischemic

About this section

PubMed Health treatment related to Stroke, Ischemic: 63

Treatment for a stroke depends on whether it is ischemic or hemorrhagic. Treatment for a transient ischemic attack (TIA) depends on its cause, how much time has passed since symptoms began, and whether you have other medical conditions. Strokes and TIAs are medical emergencies. If you have stroke symptoms, call 9–1–1 right away. Do not drive to the hospital or let someone else drive you. Call an ambulance so that medical personnel can begin life-saving treatment on the way to the emergency room. During a stroke, every minute counts. Once you receive initial treatment , your doctor will try to treat your stroke risk factors and prevent complications.

Drugs for Stroke, Ischemic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 735)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
2
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
3
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
4
Thrombin Approved, Investigational Phase 4
5
Argatroban Approved, Investigational Phase 4 74863-84-6 152951 92722
6
Enalaprilat Approved Phase 4 76420-72-9 6917719 5462501
7
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5388962 5362032
8
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
9
Propafenone Approved Phase 4 34183-22-7, 54063-53-5 4932
10
Dronedarone Approved Phase 4 141626-36-0 208898
11
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
12
Edaravone Approved, Investigational Phase 4 89-25-8 4021 70335
13
Allopurinol Approved Phase 4 315-30-0 2094 135401907
14
Insulin aspart Approved Phase 4 116094-23-6 16132418
15
Insulin glargine Approved Phase 4 160337-95-1 118984454
16
Pravastatin Approved Phase 4 81093-37-0 54687
17
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
18
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
19
Chlorhexidine Approved, Vet_approved, Withdrawn Phase 4 55-56-1 2713 9552079
20
Atenolol Approved Phase 4 29122-68-7 2249
21
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Dextromethorphan Approved Phase 4 125-71-3 5362449 5360696
24
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
25
Trazodone Approved, Investigational Phase 4 19794-93-5 5533
26
Saxagliptin Approved Phase 4 361442-04-8 11243969
27
Galantamine Approved Phase 4 357-70-0, 1953-04-4 9651
28
Quinidine Approved, Investigational Phase 4 56-54-2, 130-95-0, 804-63-7 1065 441074 3034034 8549
29
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
30
Triflusal Approved, Investigational Phase 4 322-79-2 9458
31
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
32
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
33
Esreboxetine Approved, Experimental, Investigational Phase 4 98769-81-4, 71620-89-8, 98819-76-2 65856
34
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
35
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
36
Doxazosin Approved Phase 4 74191-85-8 3157
37
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
38
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
39
Ramipril Approved Phase 4 87333-19-5 5362129
40
Manidipine Approved, Investigational Phase 4 89226-50-6 4008
41
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
42
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
43
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
44
Racephedrine Approved, Experimental Phase 4 299-42-3, 90-82-4, 90-81-3 5032 9294 7028
45
Phenylephrine Approved Phase 4 59-42-7 6041
46
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
47
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
48
Probucol Approved, Investigational Phase 4 23288-49-5 4912
49
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
50
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052

Interventional clinical trials:

(show top 50) (show all 6844)
# Name Status NCT ID Phase Drugs
1 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Unknown status NCT02684825 Phase 4
2 The Potential Effect of Omega3 Supplement in Fish Oil on Infarced Areas in the Brain and Improvement of Neurological Functions fo Ischemic Stroke Patients Unknown status NCT04386525 Phase 4
3 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo
4 Clinical Study of Argatroban in the Treatment of Acute Progressive Ischemic Stroke Unknown status NCT04275180 Phase 4 Argatroban
5 Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study Unknown status NCT02767999 Phase 4 Fluoxetine;Placebo
6 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
7 The Differentiation and Treatment Scheme of TCM Key Syndromes for the Treatment of Acute Disabling Ischemic Stroke: a Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Unknown status NCT04199455 Phase 4 Integrative Treatment (EPACH Recipe Granules + NQABC Recipe Granules);Placebo
8 Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial. Unknown status NCT02728180 Phase 4 Xingnaojing injection
9 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
10 A Randomized, Controlled, Double-blind, Multi-center Clinical Study of Shengdi Dahuang Decoction in the Treatment of Acute Hemorrhagic Stroke Unknown status NCT04200781 Phase 4 Granules of Shengdi Dahuang Decoction;Placebo
11 An International Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Progesterone Combined Intranasal and Intramuscular Administration in Patients With Acute Hemorrhagic Stroke Unknown status NCT04143880 Phase 4 Progesterone
12 Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke Unknown status NCT02581371 Phase 4 Cerebrolysin infusion
13 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
14 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
15 Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial Unknown status NCT03993236 Phase 4 Experimental: Rosuvastatin/Ezetimibe 10;Active Comparator: Rosuvastatin 20mg
16 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
17 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
18 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
19 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4
20 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
21 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
22 Safety and Efficacy of the Tong-Fu-Xing-Shen Herbal Formula for Stroke-Associated Pneumonia (TFXSHF) Unknown status NCT04275219 Phase 4 Tongfu capsules;The Placebo of Tongfu capsules
23 Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy Unknown status NCT02122367 Phase 4
24 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
25 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
26 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
27 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
28 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
29 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
30 A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and Cardiovascular Events and to Compare the Preventive Effect of Probucol in the Same Patient Group With Non-drug User Group for the Prevention of Cardiovascular Events Unknown status NCT01013532 Phase 4 Cilostazol;Probucol;Aspirin;placebo of cilostazol;placebo of aspirin
31 Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
32 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
33 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
34 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
35 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
36 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
37 An Open-Label Prospective Study to Evaluate the Safety and Efficacy of Double or Triple Concentrated Intravenous Nicardipine for Treatment of Hypertension in Patients With Ischemic Stroke, Intracerebral Hemorrhage or Subarachnoid Hemorrhage Unknown status NCT00325793 Phase 4 Nicardipine
38 Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients Unknown status NCT02484027 Phase 4 Rosuvastatin
39 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
40 Device Closure Versus Medical Therapy for Secondary Prevention in Cryptogenic Stroke Patients With High-Risk Patent Foramen Ovale : DEFENSE-PFO Unknown status NCT01550588 Phase 4 Standard medical treatment
41 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
42 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
43 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
44 TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT Unknown status NCT03529149 Phase 4
45 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Unknown status NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
46 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
47 A Randomized Study Aimed at Comparing Activated Partial Thromboplastin Time and Anti-Xa Activity and in Patients Requiring Unfractionated Heparin Infusion Unknown status NCT03426982 Phase 4 Unfractionated heparin
48 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
49 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
50 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo

Search NIH Clinical Center for Stroke, Ischemic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Dantrolene
Dantrolene Sodium
heparin
heparin calcium
heparin sodium
HEPARIN SODIUM (BEEF LUNG)
heparin sodium, bovine
heparin sodium, porcine
Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Stroke, Ischemic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Stroke, Ischemic:
ALD-401, bone marrow-derived cells for stroke
Autologous bone marrow-derived mononuclear cells for treatment of acute ischemic stroke
Bone marrow-derived mononuclear cells for ischemic stroke
Bone marrow-derived mononuclear cells for ischemic stroke
Cerecellgram-Stroke, bone marrow-derived mesenchymal stem cells for treatment of ischemic stroke
Embryonic stem cell-derived neural stem cells for ischemic stroke
Mesenchymal stem cell-derived neuronal progenitor cells for the treatment of ischemic brain damage
Mesenchymal stem cells for ischemic stroke
MultiStem, bone marrow-derived cells for ischemic and neonatal stroke
NSI-566, spinal cord stem cells for neurological disorders
Olfactory ensheathing cells transplantion for treatment of old stroke ischemic patients
PDA001, Placenta-derived cells for ischemic stroke
ReN001, human neural stem cells for the treatment of stroke
SB623, Notch1-transfected mesenchymal stem cells for stroke
Stemedyne-MSC, mesenchymal stem cells for ischemic stroke
Umbilical cord blood-derived CD34+ stem cells for treatment of chronic ischemic stroke
Umbilical cord-derived mesenchymal stem cells for treatment of stroke
Embryonic/Adult Cultured Cells Related to Stroke, Ischemic:
Bone marrow-derived ALDH+ cells (ALD) PMIDs: 10430905
Bone marrow-derived mononuclear cells (family) PMIDs: 22960888
Bone marrow-derived mononuclear cells PMIDs: 20395386 20629187
Bone marrow-derived mononuclear cells PMIDs: 17635049
Bone marrow-derived mesenchymal stem cells (Cerecellgram-Stroke)
Neural stem cells PMIDs: 18286199
Neural progenitor cells PMIDs: 21300404
Bone marrow-derived mesenchymal stem cells (family)
Bone marrow-derived adherent progenitor cells (MultiStem) PMIDs: 22952736 21175285
Fetal spinal cord stem cells (NSI-566) PMIDs: 22415942 19326469
Olfactory ensheathing cells
Placenta-derived cells
Neural stem cell line (CTX0E03) PMIDs: 19633272 23185625 17981710
Trophic factor-induced mesenchymal stem cells PMIDs: 19530164 23430693 20350349 21982515
Notch-transfected mesenchymal stromal cells (SB623) PMIDs: 19530164 23430693 20350349 21982515
Bone marrow-derived mesenchymal stem cells (Stemedyne-MSC, itMSC) PMIDs: 23295150
Umbilical cord blood-derived hematopoietic stem cells (family)
Umbilical cord-derived mesenchymal stem cells

Cochrane evidence based reviews: cerebral infarction

Sources

Genetic Tests for Stroke, Ischemic

About this section

Genetic tests related to Stroke, Ischemic:

# Genetic test Affiliating Genes
1 Ischemic Stroke 28 ALOX5AP F2 F5 NOS3 PRKCH
Sources

Anatomical Context for Stroke, Ischemic

About this section

Organs/tissues related to Stroke, Ischemic:

MalaCards : Brain, Bone Marrow, Heart, Spinal Cord, Bone, Cortex, Placenta
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Stroke, Ischemic:
# Tissue Anatomical CompartmentCell Relevance
1 Bone Bone Marrow Bone Marrow Stromal Cells Potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
Sources

Publications for Stroke, Ischemic

About this section

Articles related to Stroke, Ischemic:

(show top 50) (show all 68174)
# Title Authors PMID Year
1
Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. 53 62 57 5
15534175 2004
2
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. 62 57 5
17165044 2007
3
A nonsynonymous SNP in PRKCH (protein kinase C eta) increases the risk of cerebral infarction. 62 57 5
17206144 2007
4
A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. 53 62 57
20378606 2010
5
Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke. 53 62 57
16550187 2006
6
Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. 53 62 57
16286536 2006
7
The soluble epoxide hydrolase gene harbors sequence variation associated with susceptibility to and protection from incident ischemic stroke. 53 62 57
16115816 2005
8
Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. 53 62 57
15640973 2005
9
The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. 53 62 57
14770184 2004
10
Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. 53 62 57
14681304 2004
11
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA. 62 57
34708996 2021
12
Failure to validate association between 12p13 variants and ischemic stroke. 62 57
20410525 2010
13
Functional SNP of ARHGEF10 confers risk of atherothrombotic stroke. 62 57
20042462 2010
14
Genomewide association studies of stroke. 62 57
19369658 2009
15
Genetic polymorphisms for the study of multifactorial stroke. 62 57
18421701 2008
16
Linking Notch signaling to ischemic stroke. 62 57
18347334 2008
17
Association of the metabolic syndrome with intracranial atherosclerotic stroke. 62 57
16043803 2005
18
DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. 53 5
15277638 2004
19
Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. 62 5
12958323 2003
20
Vascular effects of statins in stroke. 62 57
9368582 1997
21
Sensitivity to cerebral ischaemic insult in a rat model of stroke is determined by a single genetic locus. 62 57
9241273 1997
22
American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. 62 57
9227708 1997
23
Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. 62 57
8696337 1996
24
Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. 62 5
7877648 1995
25
A study of twins and stroke. 62 57
1561651 1992
26
Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. 62 57
1969518 1990
27
Clinical observation of acupuncture combined with modern rehabilitation in the treatment of limb motor dysfunction after ischemic stroke: A randomized controlled trial. 62 41
36397362 2022
28
A clinical application study of a stent placement assessment. 62 41
36451472 2022
29
Stroke prevention of thoracoscopic left atrial appendage clipping in patients with non-valvular atrial fibrillation at high risk of stroke and bleeding: study protocol for a non-randomised controlled clinical trial. 62 41
36307161 2022
30
Whole-genome sequencing of patients with rare diseases in a national health system. 5
32581362 2020
31
Association study of the polymorphisms on chromosome 12p13 with atherothrombotic stroke in the Japanese population. 57
20448654 2010
32
Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. 5
19531787 2009
33
ACE D/I polymorphism, migraine, and cardiovascular disease in women. 5
19221299 2009
34
Genetically elevated C-reactive protein and ischemic vascular disease. 57
18971492 2008
35
Telomere length predicts poststroke mortality, dementia, and cognitive decline. 57
16685698 2006
36
Genetic association between endothelial nitric oxide synthase and Alzheimer disease. 5
16813604 2006
37
Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24,000 years ago. 5
16493002 2006
38
R255h amino acid substitution of protein Z identified in patients with factor V Leiden mutation. 5
15638861 2005
39
The Glu298Asp variant of the endothelial nitric oxide synthase gene is associated with an increased risk for abruptio placentae in pre-eclampsia. 5
16059745 2005
40
Angiotensin converting enzyme gene polymorphism and cardiovascular morbidity and mortality: the Rotterdam Study. 5
15635071 2005
41
The effects of the ACE gene insertion/deletion polymorphism on glucose tolerance and insulin secretion in elderly people are modified by birth weight. 5
15531537 2004
42
ACE1 polymorphism and progression of SARS. 5
15381116 2004
43
A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. 5
15110771 2004
44
Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. 5
15007011 2004
45
Factor V Leiden and the risk for venous thromboembolism in the adult Danish population. 5
14996674 2004
46
Alzheimer disease risk and genetic variation in ACE: a meta-analysis. 5
14872014 2004
47
Angiotensin-converting enzyme DD genotype is associated with worse perinatal cardiorespiratory adaptation in preterm infants. 5
14657821 2003
48
Genetics of common polygenic stroke. 57
14517535 2003
49
Phenotype modulators in myophosphorylase deficiency. 5
12666117 2003
50
New players in the genetics of stroke. 57
12444190 2002
Sources

Variations for Stroke, Ischemic

About this section

ClinVar genetic disease variations for Stroke, Ischemic:

5 (show top 50) (show all 73)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GRN NM_002087.4(GRN):c.*78C>T SNV Affects
 29742 rs5848 GRCh37: 17:42430244-42430244
GRCh38: 17:44352876-44352876
2 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu) SNV Pathogenic
 13653 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
3 CD36 NM_001001548.3(CD36):c.120+1G>A SNV Pathogenic
 1708387 GRCh37: 7:80276177-80276177
GRCh38: 7:80646861-80646861
4 ACSL4 GRCh37/hg19 Xq23(chrX:108919564-108929311) CN LOSS Pathogenic
 548953 GRCh37: X:108915663-108933582
GRCh38:
5 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg) SNV Pathogenic
 812745 rs1555729455 GRCh37: 19:15302816-15302816
GRCh38: 19:15192005-15192005
6 ADA2 NM_001282225.2(ADA2):c.1078A>G (p.Thr360Ala) SNV Pathogenic
 189342 rs775440641 GRCh37: 22:17669232-17669232
GRCh38: 22:17188342-17188342
7 FBN1 NM_000138.5(FBN1):c.5788+5G>A SNV Pathogenic
 42394 rs193922219 GRCh37: 15:48738898-48738898
GRCh38: 15:48446701-48446701
8 MT-TL1 NC_012920.1:m.3243A>G SNV Pathogenic
 9589 rs199474657 GRCh37: MT:3243-3243
GRCh38: MT:3243-3243
9 NOTCH3 NM_000435.3(NOTCH3):c.457C>T (p.Arg153Cys) SNV Pathogenic
 208501 rs797045014 GRCh37: 19:15302993-15302993
GRCh38: 19:15192182-15192182
10 LDLR NM_000527.5(LDLR):c.682G>A (p.Glu228Lys) SNV Pathogenic
 3691 GRCh37: 19:11216264-11216264
GRCh38: 19:11105588-11105588
11 NOTCH3 NM_000435.3(NOTCH3):c.227G>A (p.Cys76Tyr) SNV Likely Pathogenic
 585600 rs1568362252 GRCh37: 19:15303301-15303301
GRCh38: 19:15192490-15192490
12 F5 NM_000130.4(F5):c.1601G>A (p.Arg534Gln) SNV Risk Factor
 642 rs6025 GRCh37: 1:169519049-169519049
GRCh38: 1:169549811-169549811
13 F2 NM_000506.5(F2):c.*97G>A SNV Risk Factor
 13310 rs1799963 GRCh37: 11:46761055-46761055
GRCh38: 11:46739505-46739505
14 ACE NM_000789.3(ACE):c.2306-117_2306-116insAF118569.1:g.14094_14382 INSERT Risk Factor
 18061 GRCh37: 17:61565892-61565893
GRCh38: 17:63488531-63488532
15 NOTCH3 NM_000435.3(NOTCH3):c.505C>T (p.Arg169Cys) SNV Likely Pathogenic
 9219 rs28933696 GRCh37: 19:15302945-15302945
GRCh38: 19:15192134-15192134
16 APOB NM_000384.3(APOB):c.10580G>A (p.Arg3527Gln) SNV Likely Pathogenic
 17890 GRCh37: 2:21229160-21229160
GRCh38: 2:21006288-21006288
17 NOS3 NM_000603.5(NOS3):c.894T>G (p.Asp298Glu) SNV Risk Factor
 14015 rs1799983 GRCh37: 7:150696111-150696111
GRCh38: 7:150999023-150999023
18 PRKCH NM_006255.5(PRKCH):c.1120G>A (p.Val374Ile) SNV Risk Factor
 4991 rs2230500 GRCh37: 14:61924239-61924239
GRCh38: 14:61457521-61457521
19 NOTCH3 NM_000435.3(NOTCH3):c.1136G>C (p.Cys379Ser) SNV Likely Pathogenic
 812744 rs1599391986 GRCh37: 19:15300140-15300140
GRCh38: 19:15189329-15189329
20 FGB NM_005141.4(FGB):c.130C>T (p.Arg44Cys) SNV Likely Pathogenic
 16382 rs121909616 GRCh37: 4:155486975-155486975
GRCh38: 4:154565823-154565823
21 MYLK2 NM_033118.4(MYLK2):c.134C>T (p.Pro45Leu) SNV Uncertain Significance
 191735 rs768640764 GRCh37: 20:30408010-30408010
GRCh38: 20:31820207-31820207
22 SOS1 NM_005633.4(SOS1):c.1627T>C (p.Ser543Pro) SNV Uncertain Significance
 372578 rs981234810 GRCh37: 2:39249942-39249942
GRCh38: 2:39022801-39022801
23 FLNA NM_001110556.2(FLNA):c.4525G>A (p.Val1509Ile) SNV Uncertain Significance
 1210296 GRCh37: X:153586886-153586886
GRCh38: X:154358518-154358518
24 ABCC6 NM_001171.6(ABCC6):c.2059G>A (p.Val687Met) SNV Uncertain Significance
 493175 rs368806440 GRCh37: 16:16276672-16276672
GRCh38: 16:16182815-16182815
25 ELN NM_000501.4(ELN):c.1358-199G>A SNV Uncertain Significance
 585051 rs781963901 GRCh37: 7:73471771-73471771
GRCh38: 7:74057441-74057441
26 FLNA NM_001110556.2(FLNA):c.5255T>C (p.Leu1752Pro) SNV Uncertain Significance
 624458 rs1363194253 GRCh37: X:153583042-153583042
GRCh38: X:154354674-154354674
27 IFIH1 NM_022168.4(IFIH1):c.1873C>A (p.His625Asn) SNV Uncertain Significance
 871826 rs749942019 GRCh37: 2:163134096-163134096
GRCh38: 2:162277586-162277586
28 PRKAG2 NM_016203.4(PRKAG2):c.590C>G (p.Pro197Arg) SNV Uncertain Significance
 374128 rs368637364 GRCh37: 7:151372600-151372600
GRCh38: 7:151675514-151675514
29 RNF213-AS1, RNF213 NM_001256071.3(RNF213):c.11659A>G (p.Lys3887Glu) SNV Uncertain Significance
 523426 rs1555673862 GRCh37: 17:78337499-78337499
GRCh38: 17:80363699-80363699
30 CD36 NM_001001548.3(CD36):c.443T>A (p.Ile148Asn) SNV Uncertain Significance
 1708388 GRCh37: 7:80292319-80292319
GRCh38: 7:80663003-80663003
31 FGA NM_021871.4(FGA):c.1048G>A (p.Gly350Arg) SNV Uncertain Significance
 1708400 GRCh37: 4:155507533-155507533
GRCh38: 4:154586381-154586381
32 FGA NM_021871.4(FGA):c.475G>A (p.Val159Ile) SNV Uncertain Significance
 1708420 GRCh37: 4:155508699-155508699
GRCh38: 4:154587547-154587547
33 NOTCH3 NM_000435.3(NOTCH3):c.2093C>G (p.Pro698Arg) SNV Uncertain Significance
 1708424 GRCh37: 19:15296349-15296349
GRCh38: 19:15185538-15185538
34 ABCC6 NM_001171.6(ABCC6):c.1068G>A (p.Met356Ile) SNV Uncertain Significance
 1708432 GRCh37: 16:16295966-16295966
GRCh38: 16:16202109-16202109
35 THPO NM_000460.4(THPO):c.-146G>A SNV Uncertain Significance
 1708434 GRCh37: 3:184095863-184095863
GRCh38: 3:184378075-184378075
36 C1R NM_001733.7(C1R):c.853C>A (p.Leu285Met) SNV Uncertain Significance
 1708435 GRCh37: 12:7241498-7241498
GRCh38: 12:7088902-7088902
37 EPHB4 NM_004444.5(EPHB4):c.1960A>T (p.Thr654Ser) SNV Uncertain Significance
 1708438 GRCh37: 7:100410527-100410527
GRCh38: 7:100812905-100812905
38 COL5A1 NM_000093.5(COL5A1):c.4051G>A (p.Gly1351Arg) SNV Uncertain Significance
 1708444 GRCh37: 9:137707458-137707458
GRCh38: 9:134815612-134815612
39 SERPINC1 NM_000488.4(SERPINC1):c.1388T>C (p.Val463Ala) SNV Uncertain Significance
 1708455 GRCh37: 1:173873034-173873034
GRCh38: 1:173903896-173903896
40 ADAMTS13 NM_139027.6(ADAMTS13):c.3420C>A (p.His1140Gln) SNV Uncertain Significance
 1708458 GRCh37: 9:136321210-136321210
GRCh38: 9:133456088-133456088
41 SOS1 NM_005633.4(SOS1):c.281T>C (p.Ile94Thr) SNV Uncertain Significance
 45355 rs397517161 GRCh37: 2:39285878-39285878
GRCh38: 2:39058737-39058737
42 CBL NM_005188.4(CBL):c.1400T>C (p.Leu467Pro) SNV Uncertain Significance
 1330151 GRCh37: 11:119149392-119149392
GRCh38: 11:119278682-119278682
43 CBL NM_005188.4(CBL):c.1243G>A (p.Gly415Ser) SNV Uncertain Significance
 1332902 GRCh37: 11:119149235-119149235
GRCh38: 11:119278525-119278525
44 MT-CO2 NC_012920.1:m.8084A>G SNV Uncertain Significance
 373996 rs1057518824 GRCh37: MT:8084-8084
GRCh38: MT:8084-8084
45 MT-CYB NC_012920.1:m.15446C>T SNV Uncertain Significance
 373995 rs1057518823 GRCh37: MT:15446-15446
GRCh38: MT:15446-15446
46 PRKCH NM_006255.5(PRKCH):c.164G>C (p.Gly55Ala) SNV Uncertain Significance
 977099 rs2045636372 GRCh37: 14:61788983-61788983
GRCh38: 14:61322265-61322265
47 RNF213-AS1, RNF213 NM_001256071.3(RNF213):c.14195A>C (p.Lys4732Thr) SNV Uncertain Significance
 210003 rs148776624 GRCh37: 17:78357601-78357601
GRCh38: 17:80383801-80383801
48 COL4A2 NM_001846.4(COL4A2):c.2185G>A (p.Gly729Arg) SNV Uncertain Significance
 496734 rs201058867 GRCh37: 13:111121653-111121653
GRCh38: 13:110469306-110469306
49 CBL NM_005188.4(CBL):c.2393CCT[1] (p.Ser799del) MICROSAT Uncertain Significance
 842157 rs755938138 GRCh37: 11:119169207-119169209
GRCh38: 11:119298497-119298499
50 IFIH1 NM_022168.4(IFIH1):c.527A>G (p.Asn176Ser) SNV Uncertain Significance
 930880 rs374205118 GRCh37: 2:163167370-163167370
GRCh38: 2:162310860-162310860

Copy number variations for Stroke, Ischemic from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 135006 2 110200000 114400000 Amplification IL1RN Ischaemic stroke
Sources

Expression for Stroke, Ischemic

About this section
LifeMap Discovery
Genes differentially expressed in tissues of Stroke, Ischemic patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ARG1 arginase 1 Blood + 11.63 0.000
Search GEO for disease gene expression data for Stroke, Ischemic.
Sources

Pathways for Stroke, Ischemic

About this section

Pathways related to Stroke, Ischemic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 12.34 PRKCH PLAT PIK3CA NOS3 FGB F5
2
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) 66
Show member pathways
 12.24 PLAT FGB F5 F2
3
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 66
Show member pathways
 12.1 FBN1 F5 F2 APOB
4
VEGF Pathway (Tocris) 70
Show member pathways
 11.53 PRKCH PIK3CA NOS3
5
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.25 FGB F2 CD36
6
Cell adhesion_Plasmin signaling 22
11.19 PLAT PIK3CA FGB
7
Fibrin complement receptor 3 signaling pathway 74
11.07 PLAT PIK3CA FGB
8
A-beta Uptake and Degradation 65
10.84 LDLR CD36 ACE
9
PAR1-mediated thrombin signaling events 61
10.56 PIK3CA NOS3 F2
10
COVID-19, thrombosis and anticoagulation 74
10.25 FGB F2
Sources

GO Terms for Stroke, Ischemic

About this section

Biological processes related to Stroke, Ischemic according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.13 ACE CD36 CDKN2B-AS1 LDLR PIK3CA
2 negative regulation of platelet activation GO:0010544 9.85 NOS3 F2
3 artery morphogenesis GO:0048844 9.85 APOB LDLR NOTCH3
4 amyloid-beta clearance by cellular catabolic process GO:0150094 9.84 LDLR CD36
5 positive regulation of cholesterol storage GO:0010886 9.81 CD36 APOB
6 cholesterol import GO:0070508 9.8 LDLR CD36
7 cholesterol transport GO:0030301 9.8 LDLR CD36 APOB
8 lipoprotein catabolic process GO:0042159 9.76 LDLR APOB
9 plasma lipoprotein particle clearance GO:0034381 9.73 LDLR CD36
10 fibrinolysis GO:0042730 9.73 PLAT FGB F2
11 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.63 PRKCH CD36 APOB
12 hemostasis GO:0007599 9.58 FGB F5 F2
13 regulation of body fluid levels GO:0050878 9.52 F5 F2
14 low-density lipoprotein particle clearance GO:0034383 9.43 LDLR CD36 APOB
15 blood coagulation GO:0007596 9.28 PLAT FGB F5 F2 CD36

Molecular functions related to Stroke, Ischemic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipoprotein particle binding GO:0071813 9.26 LDLR CD36
2 thrombospondin receptor activity GO:0070053 8.92 F2 CD36
Sources

Sources for Stroke, Ischemic

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....